Skip to content

EBIT at other companies

Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
CTO
Citius Oncology, Inc.CTOR
-$28.61M-283%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$20.9M-42.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
-$23.52M-54.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Calculated from OS Therapies’s reported figures.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's EBIT?
OS Therapies (OSTX) reported EBIT of -$10.17M in Q1 2026.
How has OS Therapies's EBIT changed year-over-year?
OS Therapies's EBIT decreased by 103.4% year-over-year, from -$5M to -$10.17M.
What is the long-term trend for OS Therapies's EBIT?
Over 2 years (2023 to 2025), OS Therapies's EBIT has grown at a 157.1% compound annual growth rate (CAGR), from -$4.34M to -$28.71M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.